{
  "source": "PA-Non-Form-Zykadia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1365-6\nProgram Non-Formulary\nMedication Zykadia® (ceritinib)*\nP&T Approval Date 7/2021, 2/2022, 4/2022, 4/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nZykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic\nlymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by\nan FDA-approved test. The National Cancer Comprehensive Network (NCCN) also recommends\nZykadia as first-line therapy for ALK-positive advanced or metastatic NSCLC, for the treatment\nof inflammatory myofibroblastic tumor (IMT) with ALK translocation,in treatment of ALK-\npositive brain metastases from NSCLC, in the treatment of ALK-positive Erdheim-Chester\nDisease, advanced, recurrent, metastatic, or inoperable inflammatory myofibroblastic tumor\n(IMT) with positive ALK translocation, and ALK-positive relapsed or refractory anaplastic large\ncell lymphoma as palliative intent therapy or second-line and subsequent therapy.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Zykadia* will be approved based on the following criterion:\na. Member is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Zykadia* will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\n(2) One of the foll",
    "Authorization\na. Zykadia* will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\n(2) One of the following:\n(a) Disease is metastatic\n(b) Disease is recurrent\n(c) Disease is advanced\n-AND-\n(3) Both of the following:\n(a) Tumor is anaplastic lymphoma kinase (ALK)-positive\n-AND-\n(b) One of the following:\ni. Provider attests the patient has a contraindication, history of intolerance,\nor that the patient is not an appropriate candidate (document reason) to\nall of the following therapies:\n• Alecensa (alectinib)\n• Alunbrig (brigatinib)\n• Lorbrena (lorlatinib)\n-OR-\nii. Both of the following:\n• Patient is currently on Zykadia therapy\n-AND-\n• Patient has not received a manufacturer supplied sample at no cost\nfrom a prescriber’s office, or any form of assistance from a Novartis\npatient assistance program (e.g. sample card which can be redeemed\nat a pharmacy for a free supply of medication) or a 30 day free trial\nfrom a pharmacy as a means to establish as a current user of\nZykadia*\n*Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom a Novartis patient assistance program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zykadia will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services Inc.\n2\n(1) Patient does not show evidence of progressive disease while on Zykadia therapy\nAuthorization will be issued for 12 months.\nC. Soft Tissue Sarcoma\n1. Initial Authorization\na. Zykadia will be approved based on the following criterion:\n(1) Diagnosis of inflammatory myofibroblastic tumor (IMT) with ALK\ntranslocation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zykadia will be approved based on the follo",
    "riterion:\n(1) Diagnosis of inflammatory myofibroblastic tumor (IMT) with ALK\ntranslocation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zykadia will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zykadia therapy\nAuthorization will be issued for 12 months.\nD. Central Nervous System (CNS) Cancers\n1. Initial Authorization\na. Zykadia will be approved based on both of the following criteria:\n(1) Diagnosis of metastatic brain cancer from NSCLC\n-AND-\n(2) Tumor is anaplastic lymphoma kinase (ALK)-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zykadia will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zykadia therapy\nAuthorization will be issued for 12 months.\nE. Histiocytic Neoplasms\n1. Initial Authorization\na. Zykadia will be approved based on all the following criteria:\n© 2025 UnitedHealthcare Services Inc.\n3\n(1) Diagnosis of Erdheim-Chester Disease\n-AND-\n(2) Disease is positive for ALK rearrangement\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zykadia will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zykadia\ntherapy.\nAuthorization will be issued for 12 months.\nF. Anaplastic Large Cell Lymphoma\n1. Initial Authorization\na. Zykadia will be approved based on all of the following criteria:\n(1) Diagnosis of anaplastic large cell lymphoma\n-AND-\n(2) Tumor is anaplastic lymphoma kinase (ALK)-positive\n-AND-\n(3) Disease is relapsed or refractory\n-AND-\n(4) Used as palliative intent therapy or second-line and subsequent therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zykadia will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zykadia therapy\nAuthorization will be issued for 12 months.\nG. NCCN Recommended Regimens\n© 2025 UnitedH",
    "d on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zykadia therapy\nAuthorization will be issued for 12 months.\nG. NCCN Recommended Regimens\n© 2025 UnitedHealthcare Services Inc.\n4\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na Coverage of oncology medications may be approved based on state mandates.\n* Zykadia is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer to\nplan specifics to determine exclusion status.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Zykadia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October\n2021.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed January 2, 2025\nProgram Non-Formulary - Zykadia (ceritinib)\nChange Control\n7/2021 New program.\n2/2022 Removed “Prior Authorization” from program title and kept Non-\nFormulary. Updated background and references. Added clinical\ncriteria for ROS1-positive or ALK-positive brain metastases from\nNSCLC.\n4/2022 Added oncology medications state mandate note.\n4/2023 Annual review. Removed ROS-1 form CNS cancer as this is no longer\nNCCN recommended. Added criteria for ALK-positive Erdheim-\nChester Disease per NCCN recommendations. Updated reference.\n2/2024 Annual review. Updated background and coverage criteria for\ninoperable inflammatory myofibroblastic tumor and anaplastic large\ncell lymphoma per NCCN. Updated reference.\n2/2025 Annua",
    "reference.\n2/2024 Annual review. Updated background and coverage criteria for\ninoperable inflammatory myofibroblastic tumor and anaplastic large\ncell lymphoma per NCCN. Updated reference.\n2/2025 Annual review. Removed ROS positive criteria from NSCLC as this is\nno longer an NCCN recommendation. Removed criteria for IMT which\nwas duplicative as this is covered under soft tissue sarcomas. Updated\nbackground and reference.\n© 2025 UnitedHealthcare Services Inc.\n5"
  ]
}